Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch

Stoke Therapeutics remains a speculative BUY, with a compelling disease-modifying approach for Dravet Syndrome and a robust RNA-based platform. Its Phase 3 EMPEROR trial for zorevunersen is now fully enrolled; top-line results expected in H2 2027, with week 28 data due late December. STOK’s $343.5M cash, milestone-rich Biogen and Acadia partnerships, and manageable burn rate provide financial runway through key catalysts. Goldman Sachs projects $44 PT, $1.5B peak sales for zorevunersen and a 75% probability of success, underlining the biotech's strong upside potential.

Since my last report for Stoke Therapeutics ( STOK ) in June 2025, the ticker is up 148%. My argument for buying the stock was three-fold: The company founders have the kind of serious science pedigree that